AMIX — Autonomix Medical Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Autonomix Medical, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 13.4 | 1.99 | 12 | 11.6 | 17 |
| Operating Profit | -13.4 | -1.99 | -12 | -11.6 | -17 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.3 | -1.99 | -15.4 | -11.4 | -16.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.3 | -1.99 | -15.4 | -11.4 | -16.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.3 | -1.99 | -15.4 | -11.4 | -16.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.8 | -1.99 | -15.4 | -11.4 | -16.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -259 | -39.6 | -344 | -136 | -48.6 |